|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
WASHINGTON—Johnson & Johnson Inc. is being drawn into a battle over how much freedom shareholders have to sue companies, in a bid by lawsuit opponents to force regulators to pick sides over investors’ access to the courts. Hal Scott, a Harvard University professor who represents a trust that owns J&J shares, filed a shareholder proposal with the company that would push shareholder disputes into private arbitration hearings, instead of federal court. J&J doesn’t want to bring the proposal up for a shareholder vote, and this week the health-care products company asked the Securities and Exchange Commission for permission to reject it.
In 2018 and 2019, Biogen (BIIB) is expected to generate revenues of $13.31 billion and $13.66 billion, respectively, compared to $12.27 billion in 2017.
J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.
Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.
Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.
The Dow portfolio has depicted weak trends in 2018, thanks to concerns surrounding trade and interest rates. Nevertheless, strong U.S. economic fundamentals are likely to aid revival.
In the latest quarter, Abbott Laboratories’ (ABT) selling, general, and administrative expenses rose YoY (year-over-year) to $2.38 billion from $2.11 billion due to its Alere acquisition and expenditure for expanding the company’s different businesses. Meanwhile, its R&D (research and development) expenses rose YoY to $574.0 million from $568.0 million due to the Alere acquisition and increased cardiovascular and neuromodulation spending. It is expected to have R&D expenses of $2.25 billion and $2.36 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $1. ...
Of the 21 analysts covering Abbott Laboratories (ABT), 18 recommend “buy” or a higher rating, and three recommend “hold.” Their mean rating for Abbott stock is 1.76, and their target price is $79.44, implying a 10.6% upside for the stock based on its December 11 closing price of $71.84.
In fiscal 2018 and fiscal 2019, Abbott Laboratories (ABT) is expected to generate revenue of $30.66 billion and $32.21 billion, respectively, compared with revenue of $27.39 billion in fiscal 2017. Meanwhile, peers Biogen (BIIB), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to have revenue of $13.31 billion, $81.35 billion, and $53.59 billion, respectively, in fiscal 2018. Abbott’s cash per share is $4.20, while Biogen, Johnson & Johnson, and Pfizer have cash per share of $21.31, $7.20, and $2.90, respectively.
The Dow 30 has been witnessing volatility in 2018 so far on account of investors' apprehension regarding investing in risky assets like equities.
In the latest trading session, Johnson & Johnson (JNJ) closed at $147.10, marking a +0.41% move from the previous day.
Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study. After 48 weeks of therapy, 84.5 percent of the 1,048 participants treated with Tremfya showed 90 percent improvement in disease symptoms, as measured by the Psoriasis Area Severity Index, compared with 70 percent on Novartis's Cosentyx, J&J said.
The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations.
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.” Their mean rating for Regeneron stock is 2.58, and their target price is $426.05, implying a 12.8% upside for the stock based on its December 10 closing price of $377.59.
'Tis the season to go bargain hunting for stocks. It might not feel like it, what with the Dow Jones Industrial Average having kicked off December by shedding nearly 1,200 points, but now is the time to do some holiday shopping in the market, especially in dividend stocks. After all, as Warren Buffett likes to say, "Be greedy when others are fearful." And the way the market has been behaving lately, it's pretty clear that fear abounds. The general retreat in share prices means valuations are down and yields are up. (Dividend yields and stock prices move in opposite directions.) That has made several large-cap, high-quality dividend stocks look mighty tempting. The Standard & Poor's 500-stock index currently trades at 15 times expected earnings, according to Yardeni Research. To find bargains, we scoured the broad-market index for large companies that trade for less than 15 times projected earnings. At the same time, we limited our search to dependable dividend payers with yields of at least 3%. After taking long-term earnings growth forecasts and analysts' opinions into account, the following five names stood out as bargain dividend stocks to buy now. SEE ALSO: 19 Best Stocks to Buy for 2019